LONDON and WATERTOWN, Mass., March 30, 2026 /PRNewswire/ -- ChemPartner is proud to announce the expansion of our European footprint with a new scientific hub at Discovery Park in Sandwich, Kent. Situated just one hour from London in one of the UK's premier innovation clusters, this facility marks a significant milestone in our global expansion. The new site is a dedicated center for preclinical and translational research, supporting client programs from early-stage in vitro screening to advance

Partnership combines Lunit's platform-agnostic AI pathology algorithms with CellCarta's global CDx development and laboratory execution to help biopharma teams de-risk assets and accelerate evidence generation and CDx launch pathways. SEOUL, South Korea and MONTREAL, March 30, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta, a leading global contract research organization (CRO) laboratory to the biopharmaceutical ind

STOCKHOLM, March 30, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indication extension application for Tryngolza® (olezarsen) for the treatment of adult patients with severe hypertriglyceridemia (sHTG) ≥880 mg/dL (≥10 mmol/L). Patients with elevated triglyceride levels have substantially higher risks of all-cause mortality, atherosclerotic cardiovascular events, and acute pancreatitis[1]. The submission is supported by results f

In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 30, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ acro

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best Analytical Services", "Best Overall Staff", and "Best Project Management". Thes

AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and Matrix-like Product (CAMP), or skin substitute, designed for the treatment of hard-to-heal wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers. The product combines multiple layers of AROA

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. CAMBRIDGE, Mass., March 29, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, today announced a drug discovery collaboration with Eli Lilly and Company ("Lilly") that uses Insilico's AI engine to accelerate the discovery and development of novel ther

NDA submission for Emcitate® successfully validated by the FDA Priority Review granted and PDUFA target action date set to September 28, 2026 Emcitate® (tiratricol) is eligible to receive a Priority Review Voucher (PRV) upon approval If approved, Emcitate® (tiratricol) would become the first approved treatment in the United States for MCT8 deficiency STOCKHOLM, SE / ACCESS Newswire / March 27, 2026 / Egetis Therapeutics (STO:EGTX) - Egetis Therapeutics AB (publ) ("Egetis" or the "

Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targets Study further details platform versatility through successful degradation of multiple therapeutically relevant targets, including inflammatory cytokine TNFα in macrophages and Schwann cells Copenhagen, Denmark, 30 March 2026 – Draupnir Bio (“Draupnir”), a biotechnology company harnessing the natural machinery

iStock/ Grandbrothers The FDA has some big verdicts lined up in the second quarter, including one for a closely watched obesity drug that many anticipate will further intensify competition in weight loss. The second quarter is looking particularly front-loaded for the FDA, which in April is expected to make a handful of highly consequential decisions. One is for a rare disease with high unmet need, while another, for a melanoma treatment, could be a bellwether for how things might change at the